Loading…
Lobbying Income
$10.6M
Filings
633
Unique Clients
25
Active Period
2014–2026
Registrant-reported income from clients on LDA filings
Largest clients by registrant-reported income
Government entities explicitly identified as targets in LDA filings
Most frequently reported lobbying issues
Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded
Pandemic and All Hazards Preparedness Act, FY24 LHHS Funding for MCM Development; H.R.2940/S.1355.PASTEUR Act of 2023
Client expense: — · Firm income: $30,000
Matched citations: H.R.2940
Pandemic and All Hazards Preparedness Act, FY24 LHHS Funding for MCM Development; H.R.2940/S.1355.PASTEUR Act of 2023
Client expense: — · Firm income: $30,000
Matched citations: S.1355
Pandemic and All Hazards Preparedness Act, FY24 LHHS Funding for MCM Development; H.R.2940/S.1355.PASTEUR Act of 2023
Client expense: — · Firm income: $20,000
Matched citations: H.R.2940
Pandemic and All Hazards Preparedness Act, FY24 LHHS Funding for MCM Development; H.R.2940/S.1355.PASTEUR Act of 2023
Client expense: — · Firm income: $20,000
Matched citations: S.1355
Pandemic and All Hazards Preparedness Act, FY24 LHHS Funding for MCM Development; H.R.2940/S.1355.PASTEUR Act of 2023
Client expense: — · Firm income: $20,000
Matched citations: H.R.2940
Pandemic and All Hazards Preparedness Act, FY24 LHHS Funding for MCM Development; H.R.2940/S.1355.PASTEUR Act of 2023
Client expense: — · Firm income: $20,000
Matched citations: S.1355
Pandemic preparedness; Antimicrobial resistance; PASTEUR Act (H.R. 3932 and S. 2076)
Client expense: — · Firm income: $10,000
Matched citations: H.R. 3932
Pandemic preparedness; Antimicrobial resistance; PASTEUR Act (H.R. 3932 and S. 2076)
Client expense: — · Firm income: $10,000
Matched citations: S. 2076
Pandemic preparedness; Antimicrobial resistance; PASTEUR Act (H.R. 3932 and S. 2076)
Client expense: — · Firm income: —
Matched citations: H.R. 3932
Pandemic preparedness; Antimicrobial resistance; PASTEUR Act (H.R. 3932 and S. 2076)
Client expense: — · Firm income: —
Matched citations: S. 2076
Medical Nutrition Equity Act of 2019
2020 · fourth_quarter · Client: HOMOLOGY MEDICINES
Drug pricing, gene therapy, and rare disease funding generally; H.R. 4393 - Advancing Access to Precision Medicine; H.R. 2507/S. 2158 Newborn Screening Saves Lives Reauthorization Act; H.R. 8045 - Genome Editing Threat Assessment Act; HR 2501 - Medical Nutrition Equity Act;
Client expense: — · Firm income: $20,000
Matched citations: HR 2501
Newborn Screening Saves Lives Reauthorization Act of 2019
2020 · fourth_quarter · Client: HOMOLOGY MEDICINES
Drug pricing, gene therapy, and rare disease funding generally; H.R. 4393 - Advancing Access to Precision Medicine; H.R. 2507/S. 2158 Newborn Screening Saves Lives Reauthorization Act; H.R. 8045 - Genome Editing Threat Assessment Act; HR 2501 - Medical Nutrition Equity Act;
Client expense: — · Firm income: $20,000
Matched citations: H.R. 2507
Advancing Access to Precision Medicine Act
2020 · fourth_quarter · Client: HOMOLOGY MEDICINES
Drug pricing, gene therapy, and rare disease funding generally; H.R. 4393 - Advancing Access to Precision Medicine; H.R. 2507/S. 2158 Newborn Screening Saves Lives Reauthorization Act; H.R. 8045 - Genome Editing Threat Assessment Act; HR 2501 - Medical Nutrition Equity Act;
Client expense: — · Firm income: $20,000
Matched citations: H.R. 4393
Genome Editing Threat Assessment Act
2020 · fourth_quarter · Client: HOMOLOGY MEDICINES
Drug pricing, gene therapy, and rare disease funding generally; H.R. 4393 - Advancing Access to Precision Medicine; H.R. 2507/S. 2158 Newborn Screening Saves Lives Reauthorization Act; H.R. 8045 - Genome Editing Threat Assessment Act; HR 2501 - Medical Nutrition Equity Act;
Client expense: — · Firm income: $20,000
Matched citations: H.R. 8045
The Newborn Screening Saves Lives Reauthorization Act of 2019
2020 · fourth_quarter · Client: HOMOLOGY MEDICINES
Drug pricing, gene therapy, and rare disease funding generally; H.R. 4393 - Advancing Access to Precision Medicine; H.R. 2507/S. 2158 Newborn Screening Saves Lives Reauthorization Act; H.R. 8045 - Genome Editing Threat Assessment Act; HR 2501 - Medical Nutrition Equity Act;
Client expense: — · Firm income: $20,000
Matched citations: S. 2158
Medical Nutrition Equity Act of 2019
2020 · third_quarter · Client: HOMOLOGY MEDICINES
Drug pricing and gene therapy, generally; H.R. 4393 - Advancing Access to Precision Medicine; H.R. 2507/S. 2158 Newborn Screening Saves Lives Reauthorization Act; H.R. 8045 - Genome Editing Threat Assessment Act; HR 2501 - Medical Nutrition Equity Act;
Client expense: — · Firm income: $10,000
Matched citations: HR 2501
Newborn Screening Saves Lives Reauthorization Act of 2019
2020 · third_quarter · Client: HOMOLOGY MEDICINES
Drug pricing and gene therapy, generally; H.R. 4393 - Advancing Access to Precision Medicine; H.R. 2507/S. 2158 Newborn Screening Saves Lives Reauthorization Act; H.R. 8045 - Genome Editing Threat Assessment Act; HR 2501 - Medical Nutrition Equity Act;
Client expense: — · Firm income: $10,000
Matched citations: H.R. 2507
Advancing Access to Precision Medicine Act
2020 · third_quarter · Client: HOMOLOGY MEDICINES
Drug pricing and gene therapy, generally; H.R. 4393 - Advancing Access to Precision Medicine; H.R. 2507/S. 2158 Newborn Screening Saves Lives Reauthorization Act; H.R. 8045 - Genome Editing Threat Assessment Act; HR 2501 - Medical Nutrition Equity Act;
Client expense: — · Firm income: $10,000
Matched citations: H.R. 4393
Genome Editing Threat Assessment Act
2020 · third_quarter · Client: HOMOLOGY MEDICINES
Drug pricing and gene therapy, generally; H.R. 4393 - Advancing Access to Precision Medicine; H.R. 2507/S. 2158 Newborn Screening Saves Lives Reauthorization Act; H.R. 8045 - Genome Editing Threat Assessment Act; HR 2501 - Medical Nutrition Equity Act;
Client expense: — · Firm income: $10,000
Matched citations: H.R. 8045
The Newborn Screening Saves Lives Reauthorization Act of 2019
2020 · third_quarter · Client: HOMOLOGY MEDICINES
Drug pricing and gene therapy, generally; H.R. 4393 - Advancing Access to Precision Medicine; H.R. 2507/S. 2158 Newborn Screening Saves Lives Reauthorization Act; H.R. 8045 - Genome Editing Threat Assessment Act; HR 2501 - Medical Nutrition Equity Act;
Client expense: — · Firm income: $10,000
Matched citations: S. 2158
Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018
2018 · fourth_quarter · Client: CELLPHIRE, INC.
Blood supply and next generation blood products provisions related within the NDAA, Defense Appropriations and S2852/HR 6378 - Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018 ("PAHPA).
Client expense: — · Firm income: $30,000
Matched citations: HR 6378
Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018
2018 · fourth_quarter · Client: CELLPHIRE, INC.
Blood supply and next generation blood products provisions related within the NDAA, Defense Appropriations and S2852/HR 6378 - Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018 ("PAHPA).
Client expense: — · Firm income: $30,000
Matched citations: S2852
SUPPORT for Patients and Communities Act
2018 · fourth_quarter · Client: EMERGENT BIOSOLUTIONS INC (F/K/A ADAPT PHARMA INC )
HR 6, Labor HHS Appropriations; CARA 2.0; POWER Act; Naloxone access provisions, generally; Opioid Package, issues relating to: naloxone access, coprescribing/opioid prescribing guidelines, Judiciary, Appropriations, Energy and Commerce, and Senate HELP provisions, generally.
Client expense: — · Firm income: $10,000
Matched citations: HR 6
Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018
2018 · third_quarter · Client: CELLPHIRE, INC.
Blood supply and next generation blood products provisions related within the NDAA, Defense Appropriations and S2852/HR 6378 - Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018 ("PAHPA).
Client expense: — · Firm income: $30,000
Matched citations: HR 6378
Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018
2018 · third_quarter · Client: CELLPHIRE, INC.
Blood supply and next generation blood products provisions related within the NDAA, Defense Appropriations and S2852/HR 6378 - Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018 ("PAHPA).
Client expense: — · Firm income: $30,000
Matched citations: S2852
Source: Senate LDA